Merck Wins R&D 100 Award
Sanger Arrayed Lentiviral CRISPR Libraries wins in Analytical/Test category
Merck received a R&D 100 Award for its Sanger Arrayed Lentiviral CRISPR Libraries—the first of its kind CRISPR libraries. R&D Magazine announced the awards at its 54th Annual R&D 100 Awards Dinner on Nov. 3 in Washington D.C.
Merck KGaA
“Advancements in gene editing with tools like CRISPR are helping our customers discover and manufacture new treatments for the most difficult conditions,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “We will continue to collaborate with the global scientific community to deliver the promise of their innovations faster and work to accelerate access to health for people everywhere.”
Merck’s Sanger Arrayed Lentiviral CRISPR Libraries won in the Analytical/Test category. These libraries are the first human and mouse arrayed lentiviral CRISPR libraries for knocking out and screening gene function. The library allows discovery of genes involved in drug resistance, human disease and a wide variety of biological processes. Researchers can use the entire library to screen the entire genome or they can select specific genes and pathways to screen using the associated clones.
This is Merck’s fifth year in a row receiving an R&D 100 Award. In 2015, the AFS water purification systems and Simplicon RNA Reprogramming Technology were named in the process/prototyping and analytical/test categories, respectively. The R&D 100 Awards span industry, academia and government-sponsored research.
Other news from the department research and development
